AABB24: Freeze-Dried Platelet-Derived Hemostatic May Be Beneficial Treatment Option

Freeze-dried platelet-derived hemostatic (FPH) maybe a viable option to help decrease bleeding in refractory thrombocytopenic patients with hematological malignancies, according to data from a new study presented during the Plenary Oral Abstract Session on Sunday morning. The data, presented by Maro Ohanian, DO, from MD Anderson Cancer Center, demonstrated that within 24 hours of administration of FPH, approximately 60% of patients achieved treatment success. “FPH contributed to decreased bleeding in patients with hematologic malignancies and platelet refractoriness,” said Ohanian.

Ohanian also noted that FPH may have additional benefits for the blood community. “FPH have a room temperature shelf life of three years, lack immunogenicity and thrombogenicity, and are heat-treated to reduce infection risk,” she said. She added that FPH may represent an important alternative for patients, particularly when there are shortages of platelets and hemostatic options are needed for patients with health risks.

As part of this study, Ohanian and her colleagues assessed 20 patients with hematologic malignancies who were treated for bleeding thrombocytopenic patients. To analyze optimal treatment options, patients were treated with either one of three FPH dose-levels or liquid-stored platelets. Treatment success was defined as cessation or decreased bleeding of the most severe bleeding site.

The results showed that at the primary bleeding site, 20% of patients had improved bleeding scores at the low dose; 40% had improved/resolved bleeding at the medium dose; and 57.2% had improved/resolved bleeding at the high dose. Three (100%) patients receiving conventional liquid-stored platelets had persistent grade 2 bleeding at 12 hrs. At 24 hours, treatment success was achieved by 60% of patients given low-dose FPH, 60% of patients given medium-dose FPH, and 57% of patients given high-dose FPH. At the same time, none of the patients receiving conventional liquid-stored platelets achieved treatment success.